Impact of additional radiotherapy on the recurrence and survival of patients with T1 esophageal squamous cell carcinoma after endoscopic submucosal disection

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048189

Enrollment

Unknown

Registered

2021-07-04

Start date

2021-07-07

Completion date

Unknown

Last updated

2022-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T1 esophageal squamous cell carcinoma

Interventions

Radiation Group:Additional radiotherapy after ESD

Control Group:No additional treatment after ESD

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.patients receiving ESD at West China hospital, Huai'an People's hospital, Cangxi Peolple's hospital, and the first Zigong People's hospital. 2.pathologically diagnosed as T1 esophageal squamous cell carcinoma

Exclusion criteria

Exclusion criteria: 1. With other concurrent malignant tumors; 2. having additional chemotherapy after ESD; 3. participating other clinical trials; 4. refusing to sign informed consent.

Design outcomes

Primary

Measure	Time frame
recurrence;radiation dosage;cost;	—

Secondary

Measure	Time frame
survival;metachronous cancer;complications of radiotherapy;	—

Countries

China

Contacts

Public ContactBing Hu

Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University

hubingnj@163.com+86 18980601278

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026